The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Synopsis
Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases
The global Antisense Oligonucleotide Therapy for the Nervous System market was valued at US$ 3590 million in 2023 and is anticipated to reach US$ 10500 million by 2030, witnessing a CAGR of 17.3% during the forecast period 2024-2030.
North American market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Antisense Oligonucleotide Therapy for the Nervous System in Neuromuscular Diseases is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Antisense Oligonucleotide Therapy for the Nervous System include Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antisense Oligonucleotide Therapy for the Nervous System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense Oligonucleotide Therapy for the Nervous System.
The Antisense Oligonucleotide Therapy for the Nervous System market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antisense Oligonucleotide Therapy for the Nervous System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense Oligonucleotide Therapy for the Nervous System companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ionis Pharmaceuticals
Biogen
Sobi
Nippon Shinyaku
Jazz Pharmaceuticals
Segment by Type
Intrathecal Injection
Intravenous Injections
Other
Segment by Application
Neuromuscular Diseases
hATTR
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapy for the Nervous System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases
The global Antisense Oligonucleotide Therapy for the Nervous System market was valued at US$ 3590 million in 2023 and is anticipated to reach US$ 10500 million by 2030, witnessing a CAGR of 17.3% during the forecast period 2024-2030.
North American market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Antisense Oligonucleotide Therapy for the Nervous System in Neuromuscular Diseases is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Antisense Oligonucleotide Therapy for the Nervous System include Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antisense Oligonucleotide Therapy for the Nervous System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense Oligonucleotide Therapy for the Nervous System.
The Antisense Oligonucleotide Therapy for the Nervous System market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antisense Oligonucleotide Therapy for the Nervous System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense Oligonucleotide Therapy for the Nervous System companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ionis Pharmaceuticals
Biogen
Sobi
Nippon Shinyaku
Jazz Pharmaceuticals
Segment by Type
Intrathecal Injection
Intravenous Injections
Other
Segment by Application
Neuromuscular Diseases
hATTR
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapy for the Nervous System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Intrathecal Injection
1.2.3 Intravenous Injections
1.2.4 Other
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Perspective (2019-2030)
2.2 Global Antisense Oligonucleotide Therapy for the Nervous System Growth Trends by Region
2.2.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antisense Oligonucleotide Therapy for the Nervous System Historic Market Size by Region (2019-2024)
2.2.3 Antisense Oligonucleotide Therapy for the Nervous System Forecasted Market Size by Region (2025-2030)
2.3 Antisense Oligonucleotide Therapy for the Nervous System Market Dynamics
2.3.1 Antisense Oligonucleotide Therapy for the Nervous System Industry Trends
2.3.2 Antisense Oligonucleotide Therapy for the Nervous System Market Drivers
2.3.3 Antisense Oligonucleotide Therapy for the Nervous System Market Challenges
2.3.4 Antisense Oligonucleotide Therapy for the Nervous System Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide Therapy for the Nervous System Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide Therapy for the Nervous System Players by Revenue (2019-2024)
3.1.2 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Players (2019-2024)
3.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antisense Oligonucleotide Therapy for the Nervous System Revenue
3.4 Global Antisense Oligonucleotide Therapy for the Nervous System Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide Therapy for the Nervous System Revenue in 2023
3.5 Global Key Players of Antisense Oligonucleotide Therapy for the Nervous System Head office and Area Served
3.6 Global Key Players of Antisense Oligonucleotide Therapy for the Nervous System, Product and Application
3.7 Global Key Players of Antisense Oligonucleotide Therapy for the Nervous System, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide Therapy for the Nervous System Breakdown Data by Type
4.1 Global Antisense Oligonucleotide Therapy for the Nervous System Historic Market Size by Type (2019-2024)
4.2 Global Antisense Oligonucleotide Therapy for the Nervous System Forecasted Market Size by Type (2025-2030)
5 Antisense Oligonucleotide Therapy for the Nervous System Breakdown Data by Application
5.1 Global Antisense Oligonucleotide Therapy for the Nervous System Historic Market Size by Application (2019-2024)
5.2 Global Antisense Oligonucleotide Therapy for the Nervous System Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antisense Oligonucleotide Therapy for the Nervous System Market Size (2019-2030)
6.2 North America Antisense Oligonucleotide Therapy for the Nervous System Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
6.4 North America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size (2019-2030)
7.2 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
7.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size (2019-2030)
8.2 Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024)
8.4 Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size (2019-2030)
9.2 Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
9.4 Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size (2019-2030)
10.2 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
10.4 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
11.1.5 Ionis Pharmaceuticals Recent Development
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Antisense Oligonucleotide Therapy for the Nervous System Introduction
11.2.4 Biogen Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
11.2.5 Biogen Recent Development
11.3 Sobi
11.3.1 Sobi Company Details
11.3.2 Sobi Business Overview
11.3.3 Sobi Antisense Oligonucleotide Therapy for the Nervous System Introduction
11.3.4 Sobi Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
11.3.5 Sobi Recent Development
11.4 Nippon Shinyaku
11.4.1 Nippon Shinyaku Company Details
11.4.2 Nippon Shinyaku Business Overview
11.4.3 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Introduction
11.4.4 Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
11.4.5 Nippon Shinyaku Recent Development
11.5 Jazz Pharmaceuticals
11.5.1 Jazz Pharmaceuticals Company Details
11.5.2 Jazz Pharmaceuticals Business Overview
11.5.3 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Introduction
11.5.4 Jazz Pharmaceuticals Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
11.5.5 Jazz Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Intrathecal Injection
Table 3. Key Players of Intravenous Injections
Table 4. Key Players of Other
Table 5. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Region (2019-2024)
Table 9. Global Antisense Oligonucleotide Therapy for the Nervous System Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Region (2025-2030)
Table 11. Antisense Oligonucleotide Therapy for the Nervous System Market Trends
Table 12. Antisense Oligonucleotide Therapy for the Nervous System Market Drivers
Table 13. Antisense Oligonucleotide Therapy for the Nervous System Market Challenges
Table 14. Antisense Oligonucleotide Therapy for the Nervous System Market Restraints
Table 15. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Players (2019-2024)
Table 17. Global Top Antisense Oligonucleotide Therapy for the Nervous System Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapy for the Nervous System as of 2023)
Table 18. Ranking of Global Top Antisense Oligonucleotide Therapy for the Nervous System Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Antisense Oligonucleotide Therapy for the Nervous System Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Antisense Oligonucleotide Therapy for the Nervous System, Headquarters and Area Served
Table 21. Global Key Players of Antisense Oligonucleotide Therapy for the Nervous System, Product and Application
Table 22. Global Key Players of Antisense Oligonucleotide Therapy for the Nervous System, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Type (2019-2024)
Table 26. Global Antisense Oligonucleotide Therapy for the Nervous System Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Type (2025-2030)
Table 28. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Application (2019-2024)
Table 30. Global Antisense Oligonucleotide Therapy for the Nervous System Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Application (2025-2030)
Table 32. North America Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2025-2030) & (US$ Million)
Table 47. Ionis Pharmaceuticals Company Details
Table 48. Ionis Pharmaceuticals Business Overview
Table 49. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product
Table 50. Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024) & (US$ Million)
Table 51. Ionis Pharmaceuticals Recent Development
Table 52. Biogen Company Details
Table 53. Biogen Business Overview
Table 54. Biogen Antisense Oligonucleotide Therapy for the Nervous System Product
Table 55. Biogen Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024) & (US$ Million)
Table 56. Biogen Recent Development
Table 57. Sobi Company Details
Table 58. Sobi Business Overview
Table 59. Sobi Antisense Oligonucleotide Therapy for the Nervous System Product
Table 60. Sobi Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024) & (US$ Million)
Table 61. Sobi Recent Development
Table 62. Nippon Shinyaku Company Details
Table 63. Nippon Shinyaku Business Overview
Table 64. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product
Table 65. Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024) & (US$ Million)
Table 66. Nippon Shinyaku Recent Development
Table 67. Jazz Pharmaceuticals Company Details
Table 68. Jazz Pharmaceuticals Business Overview
Table 69. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product
Table 70. Jazz Pharmaceuticals Revenue in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024) & (US$ Million)
Table 71. Jazz Pharmaceuticals Recent Development
Table 72. Research Programs/Design for This Report
Table 73. Key Data Information from Secondary Sources
Table 74. Key Data Information from Primary Sources
Table 75. Authors List of This Report
List of Figures
Figure 1. Antisense Oligonucleotide Therapy for the Nervous System Picture
Figure 2. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Type: 2023 VS 2030
Figure 4. Intrathecal Injection Features
Figure 5. Intravenous Injections Features
Figure 6. Other Features
Figure 7. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2024-2030) & (US$ Million)
Figure 8. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Application: 2023 VS 2030
Figure 9. Neuromuscular Diseases Case Studies
Figure 10. hATTR Case Studies
Figure 11. Other Case Studies
Figure 12. Antisense Oligonucleotide Therapy for the Nervous System Report Years Considered
Figure 13. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Region: 2023 VS 2030
Figure 16. Global Antisense Oligonucleotide Therapy for the Nervous System Market Share by Players in 2023
Figure 17. Global Top Antisense Oligonucleotide Therapy for the Nervous System Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapy for the Nervous System as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide Therapy for the Nervous System Revenue in 2023
Figure 19. North America Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Antisense Oligonucleotide Therapy for the Nervous System Market Share by Country (2019-2030)
Figure 21. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Share by Country (2019-2030)
Figure 25. Germany Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Market Share by Region (2019-2030)
Figure 33. China Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Antisense Oligonucleotide Therapy for the Nervous System Market Share by Country (2019-2030)
Figure 41. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Share by Country (2019-2030)
Figure 45. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. UAE Antisense Oligonucleotide Therapy for the Nervous System Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Ionis Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
Figure 49. Biogen Revenue Growth Rate in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
Figure 50. Sobi Revenue Growth Rate in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
Figure 51. Nippon Shinyaku Revenue Growth Rate in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
Figure 52. Jazz Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotide Therapy for the Nervous System Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
